CSL (OTCMKTS:CSLLY) Raised to “Moderate Buy” at Royal Bank Of Canada

CSL (OTCMKTS:CSLLY) was upgraded by equities researchers at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a report released on Tuesday, Zacks reports.

CSLLY has been the topic of several other research reports. Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

CSL Price Performance

Shares of CSLLY stock opened at $30.65 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. CSL has a fifty-two week low of $16.01 and a fifty-two week high of $36.28. The stock’s 50-day simple moving average is $25.97 and its 200-day simple moving average is $23.34.

About CSL

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.